Company Overview of Novo Nordisk, Inc.
Novo Nordisk, Inc. operates as a healthcare company that focuses on diabetes care. The company provides diabetes pharmaceuticals and insulin delivery systems. It also specializes in hemophilia care, growth hormone therapy, and hormone replacement therapy. The company was incorporated in 1982 and is headquartered in Princeton, New Jersey. It has a manufacturing facility in Clayton, North Carolina; and a research and development center in Seattle, Washington. Novo Nordisk, Inc. operates as a subsidiary of Novo Nordisk A/S.
100 College Road West
Princeton, NJ 08540
Founded in 1982
Key Executives for Novo Nordisk, Inc.
Senior Vice President of Finance and Operations
Chief Executive Officer of Novo Nordisk A/S and President of Novo Nordisk A/S
Corporate Vice President and General Counsel
Chief Compliance Officer and Vice President of Compliance
Compensation as of Fiscal Year 2015.
Novo Nordisk, Inc. Key Developments
Novo Nordisk Announces the Latest Interim Data from the Guardian 2 Extension Trial
Jun 24 15
At the International Society on Thrombosis and Haemostasis 2015 Congress, Novo Nordisk announced the latest interim data from the guardian 2 extension trial, which showed that in a phase 3 trial, Zonovate, provided long-term efficacy and safety in the prophylaxis and treatment of bleeds in people with severe haemophilia A. The pivotal guardian clinical programme was one of the large and most comprehensive preregistration clinical trial programmes in haemophilia A, with more than 210 patients with severe haemophilia A treated. Interim data collected through December 31, 2013 from 451.6 patient-years on Zonovate show results consistent with previous reports: The overall estimated median annual bleeding rate achieved during the preventive regimen with Zonovate was 1.56. During the preventive regimen, 90% of all bleeding episodes were successfully treated with one or two infusions of Zonovate. Guardian 2 is a large, multinational extension trial of Zonovate in previously treated patients with haemophilia A from 19 countries who had been enrolled in the pivotal guardian™1 and guardian 3 trials. Patients received Zonovate in a prophylactic regimen and to treat breakthrough bleeds. These findings now comprise more than four years of data and more than 450 patient years. No inhibitors to factor VIII were detected and no safety issues were identified, supporting the findings from guardian 1 and 3, demonstrating no confirmed inhibitor development in 213 previously treated patients. The most common adverse reactions seen in the study were injection-site reactions, increased hepatic enzymes and fever.
Novo Nordisk Inc. Wins $532.61 Million Federal Contract
Jun 3 15
Novo Nordisk Inc. won a $532,607,180 federal contract from the U.S. Department of Veterans Affairs National Acquisition Center, Hines, Illinois, for human insulin. The contract has four option years.
Novo Nordisk, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Novo Nordisk, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|